Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAROS pediatric asthma glycopyrronium dose-ranging crossover study
2025-524914-26-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in asthma, sponsored by AstraZeneca. Primary endpoint: Change from baseline in FEV1 at 1 hour post-dose measured at end of treatment. Planned start Jul 2026; status: authorised.
02
Drugs
glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on 2025-524914-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524914-26-00.